Colorectal cancer was estimated to have the fourth newest incident rate and to have the second highest death rate in 2015 according to the American Cancer Society. There were an estimated 132,700 new diagnoses of colorectal cancer made and approximately 69,000 deaths in 2015 attributing to this form of cancer. 5-fluorouracil (5-FU) or 5-FU with oxaliplatin (FOLFOX) continues to be the standard treatment protocol for patients presenting with colorectal cancer. However, treatment with FOLFOX and conventional chemotherapy has shown to lead to cancer recurrence and a number of toxic side effects. Alternative therapies based on natural ingredients show promise in combating cancer by inhibiting tumorigenic pathways, such as mTORC (mammalian target of rapamycin complex), c-MYC oncogene, and the COX-2 pathway. Using natural based agents and morphoproteomic-guided targeted therapy, the goal of this study was to evaluate the effectiveness of such an approach in a chemotherapy resistant, colon cancer patient. This case report describes a 46-year old woman with a non-metastasizing colorectal cancer that showed "minimal treatment effect" with chemotherapy despite being compliant. As of May 2016, CT scans and colonoscopy confirmed that the cancer was in remission after that patient had been compliant with morphoproteomic-guided, natural therapies for nine months.
© 2017 by the Association of Clinical Scientists, Inc.